Výsledky vyhledávání

Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer : The CEBIFOX Trial

Background The multicenter, single-arm, phase II study CEBIFOX evaluated the efficacy of a biweekly cetuximab administration in combination with FOLFOX6 as first-line therapy in KRAS (exon 2) wild-type (wt) metastatic colorectal cancer (mCRC). Patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5696b5ebc448e4c4fa8e944cdfb072ca
https://www.ncbi.nlm.nih.gov/pubmed/32737003

Zobrazit plný text záznamu

Severe Hypoglycemia Caused by Paraneoplastic Production of IGF-II in Patients With Advanced Gastrointestinal Stromal Tumors: A Report of Two Cases

Autor: Udo Vanhoefer, Peter Reichardt, Heike Knipp, Albrecht Kretzschmar, D. Schoeler, Daniel Pink, Peter C. Thuss-Patience, T. Lindner

Publikováno v: Journal of Clinical Oncology. 23:6809-6811

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::195677b68c33d0f1ab8049ff4dc53d7d
https://doi.org/10.1200/jco.2005.02.4828

Zobrazit plný text záznamu

Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trial

Autor: Tanja Trarbach, Thomas Herold, Gabriele Linden, Saskia Ting, Karl Worm, Karina Kostbade, Peter Markus, Johannes Meiler, Brigitte Schumacher, Heike Knipp, Stefan Kasper, H.T. Steinmetz, Peter Reimer, Martin Schuler, T. Höhler, Kurt Werner Schmid, Winfried Berger, Andreas Paul, Alexander Dechêne

Publikováno v: Annals of Oncology. 27:vi167

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::033e7056cc233ee132703dd9ae54561e
https://doi.org/10.1093/annonc/mdw370.56

Zobrazit plný text záznamu

5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus

Autor: Hans-Joachim Schmoll, Ulf Fink, Michael Stahl, P. Preusser, Hans-Joachim Meyer, Thomas Berns, Hansjochen Wilke, Wolf Achterrath, Heike Knipp, Andreas Harstrick, Michael Berger

Publikováno v: European Journal of Cancer. 30:325-328

38 patients with advanced oesophageal carcinoma were treated with intravenous (i.v.) folinic acid (300 mg/m2), 5-fluorouracil (500 mg/m2), etoposide (100 mg/m2), and cisplatin (30 mg/m2) (FLEP), on days 1, 2 and 3, every 22-28 days. 26 patients had l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd1ea71baf068067a40a80908e9e703e
https://doi.org/10.1016/0959-8049(94)90250-x

Zobrazit plný text záznamu

Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC): Primary endpoint and subgroup analysis of the CEBIFOX trial

Autor: Karina Kosbade, Kurt Werner Schmid, Tilman Steinmetz, Peter Reimer, Thomas Herold, Johannes Meiler, Martin Schuler, Tanja Trarbach, Saskia Ting, Andreas Paul, Winfried Berger, Brigitte Schumacher, Gabriele Linden, Alexander Dechêne, Karl Worm, Stefan Kasper, Heike Knipp, Thomas Hoehler, Peter Markus

Publikováno v: Journal of Clinical Oncology. 33:3568-3568

3568 Background: The multicenter, single-arm, phase II CEBIFOX trial (Simon`s two stage minimax design) evaluated the efficacy of mFOLFOX6 + biweekly cetuximab (500 mg/m2) as 1st line therapy in KR...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::773bb2cedb4cf40e6a55de6a433b8bb6
https://doi.org/10.1200/jco.2015.33.15_suppl.3568

Zobrazit plný text záznamu

Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC): An interim analysis of the CEBIFOX trial

Autor: Saskia Ting, Stefan Kasper, Martin Schuler, Thomas Hoehler, Peter Markus, Andreas Paul, Heike Knipp, Tanja Trarbach, Tilman Steinmetz, Peter Reimer, Winfried Berger, Johannes Meiler, Gabriele Linden

Publikováno v: Journal of Clinical Oncology. 31:e14502-e14502

e14502 Background: Combination of mFOLFOX6 with weekly cetuximab is a standard first line regimen in pts with KRAS wt mCRC. Weekly application of cetuximab increases the in-hospital time of pts with negative impact on quality of life. This multicentr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a3d4c58dd4c2c99d31331ab4feb34dd
https://doi.org/10.1200/jco.2013.31.15_suppl.e14502

Zobrazit plný text záznamu

Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus

Autor: Michael Stahl, P. Preusser, Claus Henning Köhne-Wömpner, Hans-Joachim Schmoll, Hans-Joachim Meyer, Andreas Harstrick, Carsten Bokemeyer, Heike Knipp, Hansjochen Wilke

Publikováno v: Cancer Chemotherapy and Pharmacology. 29:321-322

A total of 26 evaluable patients presenting with advanced or metastatic squamous-cell carcinoma of the esophagus were entered in a phase II trial to assess the single-agent activity of etoposide. Etoposide was given at a dose of 200 mg/m2 on 3 consec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e50637d045cbfb3f40c088db64e17be
https://doi.org/10.1007/bf00685952

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání